Literature DB >> 31896038

Association between frequency of primary care provider visits and evidence-based statin prescribing and statin adherence: Findings from the Veterans Affairs system.

Sarah T Ahmed1, Dhruv Mahtta2, Hasan Rehman3, Julia Akeroyd1, Mahmoud Al Rifai4, Fatima Rodriguez5, Hani Jneid4, Khurram Nasir6, Zainab Samad7, Mahboob Alam4, Laura A Petersen1, Salim S Virani8.   

Abstract

BACKGROUND: Statin use remains suboptimal in patients with atherosclerotic cardiovascular disease (ASCVD). We assessed if the frequency of visits with primary care providers (PCPs) is associated with higher use of evidence-based statin prescriptions and adherence among patients with ASCVD.
METHODS: We identified patients with ASCVD aged ≥18 years receiving care in 130 facilities and associated community-based outpatient clinics in the entire Veterans Affairs Health Care System between October 1, 2013 and September 30, 2014. Patients were divided into frequent PCP visitors (annual PCP visits ≥ median number of PCP visits for the entire cohort) and infrequent PCP visitors (annual PCP visits < median number of patient visits). We assessed any- and high-intensity statin prescription as well as statin adherence which was defined by proportion of days covered (PDC).
RESULTS: We included 1,249,061 patients with ASCVD (mean age was 71.9 years; 98.0% male). Median number of annual PCP visits was 3. Approximately 80.1% patients were on statins with 23.8% on high-intensity statins. Mean PDC was 0.715 ± 0.336 with 58.3% patients with PDC ≥0.8. Frequent PCP visitors had higher frequency of statin use (82.2% vs 77.4%), high-intensity statin use (26.4% vs 20.3%), and statin adherence (mean PDC 0.73 vs 0.68; P < .01) compared to infrequent PCP visitors. After adjusting for covariates, frequent PCP visits was associated with greater odds of being on any statin, high intensity statin, and higher statin adherence.
CONCLUSION: Frequent visits with PCPs is associated with a higher likelihood of any statin use, high intensity statin use, and statin adherence. Further research endeavors are needed to understand the reasons behind these associations. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31896038     DOI: 10.1016/j.ahj.2019.11.019

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  6 in total

1.  Forecasting the physician assistant/associate workforce: 2020-2035.

Authors:  Roderick S Hooker; Violet Kulo; Gerald Kayingo; Hyun-Jin Jun; James F Cawley
Journal:  Future Healthc J       Date:  2022-03

2.  Utilisation of government-subsidised chronic disease management plans and cardiovascular care in Australian general practices.

Authors:  Genevieve Coorey; Anna Campain; John Mulley; Tim Usherwood; Julie Redfern; Mark Harris; Nicholas Zwar; Sharon Parker; Enrico Coiera; David Peiris
Journal:  BMC Prim Care       Date:  2022-06-21

3.  Cardiology clinic visit increases likelihood of evidence-based cholesterol prescribing in severe hypercholesterolemia.

Authors:  Nicole A Groth; Neil J Stone; Catherine P Benziger
Journal:  Clin Cardiol       Date:  2020-12-23       Impact factor: 2.882

4.  Primary care physician volume and quality of care for older adults with dementia: a retrospective cohort study.

Authors:  Natasha E Lane; Vicki Ling; Richard H Glazier; Thérèse A Stukel
Journal:  BMC Fam Pract       Date:  2021-03-09       Impact factor: 2.497

5.  Factors affecting statin uptake among people living with HIV: primary care provider perspectives.

Authors:  Allison J Ober; Sae Takada; Deborah Zajdman; Ivy Todd; Tamara Horwich; Abraelle Anderson; Soma Wali; Joseph A Ladapo
Journal:  BMC Fam Pract       Date:  2021-10-30       Impact factor: 2.497

6.  An Evaluation of Statin Use Among Patients with Type 2 Diabetes at High Risk of Cardiovascular Events Across Multiple Health Care Systems.

Authors:  Ralph Ward; Erin R Weeda; Kinfe G Bishu; R Neal Axon; David J Taber; Mulugeta Gebregziabher
Journal:  J Manag Care Spec Pharm       Date:  2020-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.